北京新领先医药科技发展有限公司
Beijing Xinlingxian Pharmaceutical (SSE: 600222) is a China-based full-chain pharmaceutical CXO offering CMC formulation, clinical CRO, and MAH regulatory services to domestic and international pharmaceutical companies via 14 nationwide offices and specialized research institutes.
- Company typePublic
- Founded2005
- HeadquartersBeijing, China
- Headcount51–100
- GTM typeB2B
- OfferingServices
What 北京新领先医药科技发展有限公司 does
Beijing Xinlingxian Pharmaceutical Technology Development Co., Ltd. (SSE: 600222), founded in 2005 and headquartered in Beijing's Zhongguancun Software Park, operates as a full-chain pharmaceutical CXO serving domestic and international pharmaceutical companies. The service portfolio spans three integrated pillars: pharmaceutical CMC R&D (covering API synthesis, excipient development, formulation development, and analytical testing), clinical CRO (operated through the Deep Blue Sea subsidiary since 2007), and MAH (Marketing Authorization Holder) services including a one-stop 'MAH Supermarket' marketplace offering approved drug dossiers and contract R&D. The company is led by Chairman 陶新华 (Tao Xinhua) with President 高世静 (Gao Shijing) overseeing group operations and the pediatric subsidiary.
Technical infrastructure includes six international-standard R&D platforms in Zhengzhou's Airport Biotech Park (compliant with FDA, EMA, and NMPA GMP standards), spanning drug screening, drug evaluation in a GLP/AAALAC/CNAS-certified animal facility, large-molecule pilot manufacturing, small-molecule CMC formulation, cell technology services, and clinical CRO. Specialized platforms include China's first domestically developed in vitro-in vivo correlation (IVIVR) platform for predicting drug absorption and improving bioequivalence (BE) pass rates, a five-center impurity research division, a transdermal drug delivery platform led by former PLA expert 颜耀东 (Yan Yaodong), a Hangzhou pediatric formulations institute, and a Chongqing advanced formulations institute using hot-melt extrusion and spray-drying technologies. Analytical capabilities include a 1,000 sqm ISO 9001-certified testing center equipped with ICP-MS, LC-MS/MS, GC-MS/MS, IC, DSC, IR, HPLC, and GC instruments.
The company operates a B2B enterprise sales model with project-based contracting, serving 500+ upstream and downstream pharmaceutical companies. Distribution is supported by a nationwide footprint spanning 14 Chinese cities (with Deep Blue Sea clinical operations in 20+ cities) and clinical partnerships with nearly 1,000 clinical research institutions and 600+ clinical hospitals covering 1,500+ hospital departments. The group fields a senior R&D management team of approximately 1,000 professionals and runs 50–100 BE studies and dozens of Class I innovative-drug projects annually. Cumulative outputs include 1,000+ pharmaceutical R&D projects, 2,000+ clinical research projects, 200+ patent applications (nearly 100 authorized), and instrument-vendor joint laboratories with Shimadzu and Thermo Fisher Scientific. The company was ranked #1 among Chinese pharmaceutical R&D enterprises in 2019 and recognized as a 2025–2026 top-50 pharmaceutical R&D enterprise and trustworthy pharmaceutical company.
北京新领先医药科技发展有限公司 firmographics
Firmographics- Name
- 北京新领先医药科技发展有限公司
- Legal name
- 北京新领先医药科技发展有限公司
- Website
- https://leadingpharm.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Beijing Xinlingxian Pharmaceutical (SSE: 600222) is a China-based full-chain pharmaceutical CXO offering CMC formulation, clinical CRO, and MAH regulatory services to domestic and international pharmaceutical companies via 14 nationwide offices and specialized research institutes.
- Ownership category
- akta.pro rank
北京新领先医药科技发展有限公司 industry classification
Industry- Product category
- Pharmaceutical Contract Research and Development Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- Drug Substance–Drug Product Integrated CDMOHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)Clinical Trial Material (CTM) Manufacturing & Supply CDMOHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)Formulation & Preclinical CMC Support (Nonclinical)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
Keywords
Where 北京新领先医药科技发展有限公司 is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices14 records
Markets served
北京新领先医药科技发展有限公司 business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- CMC Pharmaceutical R&D Services: Provides comprehensive pharmaceutical CMC (Chemistry, Manufacturing, and Controls) R&D services including raw material, excipient, formulation development, and analytical testing. Revenue generated through project-based service contracts.
- Clinical CRO Services: Clinical research organization services including Phase I-IV clinical trials, bioequivalence studies, PK/PD research, and medical affairs. Provided through subsidiary Deep Blue Sea.
- MAH Services: Marketing Authorization Holder services including project filing, regulatory affairs, and quality management. Also operates 'MAH Supermarket' offering product approvals and commissioned R&D.
- CDMO Manufacturing: Contract development and manufacturing organization services through six international-standard platforms in Zhengzhou Airport Bio-industrial Park.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
北京新领先医药科技发展有限公司 product offering
Product offeringCore offering
Beijing Xinlingxian (stock code 600222) provides full-industry-chain pharmaceutical R&D services covering pharmaceutical CMC R&D (API synthesis, formulation development, analytical testing, IVIVR modeling), clinical CRO (Phase I-IV trials, bioequivalence studies, PK/PD research), MAH (Marketing Authorization Holder) services, and CDMO manufacturing through six international-standard (FDA, EMA, NMPA GMP) platforms for domestic and international pharmaceutical companies.
Product overview
北京新领先医药科技发展有限公司 (股票代码600222) operates a unified CXO (Contract X Organization) full-industry-chain service platform for pharmaceutical R&D. The portfolio consists of three core integrated service pillars: (1) 研发CMC平台 — covering API synthesis, excipient R&D, formulation development, analytical testing, and in vivo/in vitro correlation; (2) 临床CRO — a nationwide clinical research operations network providing Phase I–IV trials, bioequivalence, PK/PD, IIT, medical affairs, and third-party audits; and (3) MAH服务 — covering project initiation, regulatory affairs, and quality management for marketing authorization holders. These are supported by specialized research institutes (郑州液体制剂一致性评价中心, 北京药学研究院, 重庆高端制剂研究院, 杭州高端儿科研究院, 透皮给药制剂平台) and specialist platforms (体内外桥接IVIVR平台, 杂质研究事业部, 分析测试中心). The company operates sub-brands including 深蓝海生物医药 and 郑州深蓝海生物医药 for clinical CRO, and offers the MAH超市 as a one-stop product dossier marketplace. All platforms are coordinated under the 新领先CXO brand with shared quality management systems (ISO9001) and international GMP compliance (FDA, EMA, NMPA).
Differentiator
Problem solved
Functional benefit
Brands
- 新领先CXO·深蓝海: 临床CRO子品牌,提供I-III期临床研究、生物等效性研究、上市后研究、第三方稽查、IND和NDA申报及医学事务等服务,涵盖生物药、化药、中药、医疗器械、细胞与基因治疗等领域。
- 郑州深蓝海生物医药
- 杭州康领先医药
Products and services
- Pharmaceutical CMC R&D Platform (药学CMC研发平台) Full drug development lifecycle services including API synthesis, excipient R&D, formulation development (generic drugs, improved new drugs, innovative drugs), analytical testing, in vivo/in vitro correlation, and regulatory registration for pharmaceutical companies.
- Clinical CRO Services (临床CRO) Full-service clinical research organization providing Phase I-IV clinical trials, bioequivalence (BE) studies, PK/PD research, IIT studies, medical affairs, third-party audits, and post-marketing surveillance for pharmaceutical sponsors across China.
- MAH Services (MAH服务) Marketing Authorization Holder (MAH) services covering project initiation, regulatory affairs consulting, full life-cycle quality management, and one-stop MAH Supermarket (MAH超市) platform offering approved drug dossiers, contract R&D, and clinical research services.
Quantifiable outcome
- Over 90% one-time bioequivalence pass rate for BE studies
- +2 more outcomes
Companies that use 北京新领先医药科技发展有限公司
Customer profileNamed customers9 records
Segments1 record
Ideal customer profiles1 record
北京新领先医药科技发展有限公司 technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
北京新领先医药科技发展有限公司 partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Deep Blue Sea Biological Medicine (深蓝海生物医药)coreDeep Blue Sea is a subsidiary brand of Xinlingxian in clinical CRO, established in 2007. It provides comprehensive clinical research services including Phase I-III clinical trials, bioequivalence studies, post-market research, and regulatory affairs. Has conducted 2000+ clinical research projects and partners with nearly 1000 clinical institutions.
- Huludao Pharmaceutical (葫芦娃药业)coreCo-founded Hangzhou Kanglingxian with Huludao Pharmaceutical in 2022 to focus on high-end pediatric formulation R&D. Kanglingxian has developed nearly 60-person R&D team and 30+ products in development, with nearly 10 receiving clinical approval.
- Shanghai HaoYuan Pharmaceutical (上海皓元医药)minorStrategic partner in the 'Four-Party Co-construction' academic-industry collaboration initiative with Beijing Normal University Chemistry Department and Lanzhou University Chemistry College for joint research and talent development.
- Beijing Normal University Chemistry College (北京师范大学化学学院)minorAcademic partner in four-party collaboration for joint research exchange,产学研 cooperation, and scientific achievement translation. BNU professor shared research progress on radiopharmaceuticals for Alzheimer's detection and cancer fluorescent probe drug development.
- Lanzhou University Chemistry and Chemical Engineering College (兰州大学化学化工学院)minorAcademic partner in four-party collaboration. Lanzhou University is home to National Key Laboratory of Functional Organic Molecules. The collaboration focuses on joint research, talent cultivation, and promoting industry-academia-research cooperation.
- Shenyang Pharmaceutical University (沈阳药科大学)minorPartner in pharmaceutical advanced professional training program. The first cohort of the jointly-run pharmaceutical advanced professional training class successfully concluded. Coursework covers pharmaceutical chemistry, pharmacology, pharmaceutics, pharmaceutical analysis, and frontier topics like green chemistry and pharmacokinetics.
- Beijing Medical University Third Hospital (北医三院)minorClinical research partner for Kanglingxian's pediatric drug development. Kanglingxian plans to establish multi-dimensional cooperation with renowned medical institutions including BUMC for pediatric clinical needs.
- CMAC Center Imaging IRC Alliance (CMAC中心影像IRC联盟)minorIndustry alliance for independent imaging review in clinical trials. Xinlingxian's VP Zhang Ronghuo was appointed as expert committee member of the inaugural IRC alliance, contributing to standardization of independent imaging assessment in clinical research.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
北京新领先医药科技发展有限公司 competitors and assessment
Company assessmentDirect peers
- JOINN Laboratories: China-based preclinical and clinical CRO with GLP-certified facilities for safety evaluation and bioanalytical services. Comparable for preclinical CMC support and safety pharmacology work that underpins CMC submissions.
- Pharmaron: Integrated drug discovery, development, and manufacturing services company with CMC, preclinical, clinical, and API manufacturing capabilities across China, US, and UK. Directly comparable as an integrated CRO/CDMO with similar full-chain service positioning.
- WuXi STA (WuXi AppTec Subsidiary): Small-molecule API and drug product CDMO arm of WuXi AppTec, the global leader in this segment. Direct competitor for Xinlingxian's small-molecule CMC formulation research and integrated CDMO offerings.
- Hangzhou Tigermed: China's leading clinical CRO with strong Phase I-IV capabilities and expanding into data sciences and biostatistics. Highly comparable through Deep Blue Sea, which competes directly with Tigermed for clinical trial projects and BE studies in China.
- Pharmablock Sciences: Chemistry-focused CRO/CDMO providing custom synthesis, building blocks, and process R&D for pharmaceutical companies. Comparable as a chemistry and small-molecule services peer, particularly relevant for API development and impurity research work.
- WuXi AppTec: Largest integrated CRO/CDMO in China and globally, offering laboratory testing, CMC, clinical CRO, and CDMO services across small and large molecules. Directly comparable as an integrated CXO platform serving similar pharmaceutical clients; the benchmark competitor that Xinlingxian must differentiate against.
- Porton Pharma: Chinese CDMO providing small molecule API and formulation CDMO services plus peptide and oligonucleotide capabilities. Comparable as a small-molecule drug product CDMO competitor, particularly relevant given Xinlingxian's CDMO manufacturing platform in Zhengzhou.
- Shanghai Medicilon: Preclinical CRO offering drug discovery, IND-enabling toxicology, and CMC services with both China and US operations. Comparable as a preclinical and early development CRO supporting pharmaceutical R&D programs from discovery through CMC.
- Asymchem Laboratories: Leading Chinese CDMO specializing in small molecule API and intermediate development/manufacturing with strong international client base. Comparable as a CMC and manufacturing services competitor, particularly for small-molecule formulation and API CDMO work.
Emerging players
- Genscript ProBio: Biologics CDMO and cell/gene therapy services arm of Genscript, focused on plasmid, viral vector, and cell therapy CMC/manufacturing. Emerging peer for Xinlingxian's biologics and large-molecule pilot/scale-up capabilities in Zhengzhou.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
北京新领先医药科技发展有限公司 social profiles
Digital presence北京新领先医药科技发展有限公司 compliance and trust
Trust signalCompliance5 records
北京新领先医药科技发展有限公司 financial estimates
Financial estimateRevenue estimate
Valuation estimate
北京新领先医药科技发展有限公司 leadership team
Management profileNumber of profiles
Profiles8 records
北京新领先医药科技发展有限公司 subsidiaries and ownership
Company hierarchySubsidiaries2 records
北京新领先医药科技发展有限公司 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
北京新领先医药科技发展有限公司 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 北京新领先医药科技发展有限公司
What does 北京新领先医药科技发展有限公司 do?
Beijing Xinlingxian (stock code 600222) provides full-industry-chain pharmaceutical R&D services covering pharmaceutical CMC R&D (API synthesis, formulation development, analytical testing, IVIVR modeling), clinical CRO (Phase I-IV trials, bioequivalence studies, PK/PD research), MAH (Marketing Authorization Holder) services, and CDMO manufacturing through six international-standard (FDA, EMA, NMPA GMP) platforms for domestic and international pharmaceutical companies.
Is 北京新领先医药科技发展有限公司 a public or private company?
北京新领先医药科技发展有限公司 is a public company. It is classified as public and is currently operating.
When was 北京新领先医药科技发展有限公司 founded?
北京新领先医药科技发展有限公司 was founded in 2005. It employs 51 to 100 people.
Where is 北京新领先医药科技发展有限公司 based?
北京新领先医药科技发展有限公司 is headquartered in Beijing, China, in the Asia region.
How does 北京新领先医药科技发展有限公司 make money?
Four revenue lines are on record. CMC Pharmaceutical R&D Services are the primary driver. The others are clinical CRO Services, MAH Services and CDMO Manufacturing.
Who are 北京新领先医药科技发展有限公司's main competitors?
Direct peers on record are JOINN Laboratories, Pharmaron, WuXi STA (WuXi AppTec Subsidiary), Hangzhou Tigermed, Pharmablock Sciences, WuXi AppTec, Porton Pharma, Shanghai Medicilon and Asymchem Laboratories. Genscript ProBio is listed as an emerging player.
Does 北京新领先医药科技发展有限公司 have an API?
No public API is recorded for 北京新领先医药科技发展有限公司.
What industry is 北京新领先医药科技发展有限公司 in?
北京新领先医药科技发展有限公司's product category is Pharmaceutical Contract Research and Development Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 5417 and its SIC code is 8731.